Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial
暂无分享,去创建一个
C. Doré | N. Modi | P. Brocklehurst | R. Carr
[1] Ofer Levy,et al. Innate immunity of the newborn: basic mechanisms and clinical correlates , 2007, Nature Reviews Immunology.
[2] Thomas J. Smith,et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Sheridan-Pereira,et al. Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Have Differential Effects on Neonatal and Adult Neutrophil Survival and Function , 2005, Pediatric Research.
[4] B. Vohr,et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. , 2004, JAMA.
[5] P. Nathan,et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Doré,et al. G-CSF and GM-CSF for treating or preventing neonatal infections. , 2003, The Cochrane database of systematic reviews.
[7] D. Isaacs,et al. A ten year, multicentre study of coagulase negative staphylococcal infections in Australasian neonatal units , 2003, Archives of disease in childhood. Fetal and neonatal edition.
[8] J. Bussel,et al. Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants , 2002, The Pediatric infectious disease journal.
[9] W. Poole,et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. , 2002, Pediatrics.
[10] T. Huizinga,et al. Low soluble FcRIII receptor demonstrates reduced neutrophil reserves in preterm neonates , 2000, Archives of disease in childhood. Fetal and neonatal edition.
[11] R. Carr. Neutrophil Production and Function in Newborn Infants , 2000, British journal of haematology.
[12] M. Lejeune,et al. Defective functional activity and accelerated apoptosis in neutrophils from children with cancer are differentially corrected by granulocyte and granulocyte‐macrophage colony stimulating factors in vitro , 1999, British journal of haematology.
[13] C. Doré,et al. A Randomized, Controlled Trial of Prophylactic Granulocyte-Macrophage Colony-Stimulating Factor in Human Newborns Less Than 32 Weeks Gestation , 1999, Pediatrics.
[14] E. L. La Gamma,et al. Preliminary Report: rhG-CSF May Reduce the Incidence of Neonatal Sepsis in Prolonged Preeclampsia-associated Neutropenia , 1998, Pediatrics.
[15] A. Leviton,et al. Infection remote from the brain, neonatal white matter damage, and cerebral palsy in the preterm infant. , 1998, Seminars in pediatric neurology.
[16] G. Ricevuti,et al. In vitro effects of GM-CSF on mature peripheral blood neutrophils. , 1998, International journal of molecular medicine.
[17] N. Modi,et al. Haemopoietic colony stimulating factors for preterm neonates , 1997, Archives of disease in childhood. Fetal and neonatal edition.
[18] M. Cairo,et al. Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils. , 1995, Blood.
[19] W. Kachel,et al. Neonatal Neutropenia in Low Birthweight Premature Infants , 1995, American journal of perinatology.
[20] P. Sánchez,et al. Revised reference ranges for circulating neutrophils in very-low-birth-weight neonates. , 1994, Pediatrics.
[21] R. Faix,et al. Increased nosocomial infection in neutropenic low birth weight (2000 grams or less) infants of hypertensive mothers. , 1992, The Journal of pediatrics.
[22] R. Frenck,et al. The ability of recombinant murine granulocyte-macrophage colony-stimulating factor to protect neonatal rats from septic death due to Staphylococcus aureus. , 1990, The Journal of infectious diseases.
[23] M. Cairo,et al. Prophylactic or Simultaneous Administration of Recombinant Human Granulocyte Colony Stimulating Factor in the Treatment of Group B Streptococcal Sepsis in Neonatal Rats , 1990, Pediatric Research.
[24] R. Christensen,et al. Incidence, neutrophil kinetics, and nautral history of neonatal neutropenia associated with maternal hypertension , 1989, The New England journal of medicine.
[25] H. Hill. Biochemical, Structural, and Functional Abnormalities of Polymorphonuclear Leukocytes in the Neonate , 1987, Pediatric Research.
[26] E. Liehl,et al. Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates. , 1987, Blood.
[27] R. Christensen,et al. Exhaustion of mature marrow neutrophils in neonates with sepsis. , 1980, The Journal of pediatrics.
[28] O. Derman,et al. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. , 2001, Pediatrics.
[29] A. Fanaroff,et al. A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates. , 1999, The Journal of pediatrics.
[30] P. Gray,et al. Neonatal neutropenia associated with maternal hypertension poses a risk for nosocomial infection , 1999, European Journal of Pediatrics.
[31] R. Christensen. Neutrophil kinetics in the fetus and neonate. , 1989, The American journal of pediatric hematology/oncology.
[32] C. Begley,et al. Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor. , 1987, Blood.